Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA <i>in situ</i> hybridization
Pavithra Dedigama-Arachchige(Henry Ford Health System), Nallasivam Palanisamy(Henry Ford Health System), Craig Rogers(Norfolk and Norwich University Hospitals NHS Foundation Trust), Dhananjay Chitale(Henry Ford Hospital), Hans Stricker(University Hospital of Bern), Ian M. Loveless(Henry Ford Health System), James O. Peabody(Henry Ford Hospital), Jia Li(Nankai University), Nilesh Gupta(Henry Ford Health System), Mani Menon(Henry Ford Hospital), Sean R. Williamson(Cleveland Clinic), Shannon Carskadon(Henry Ford Health System), Tarek A. Bismar(University of Calgary)
Cited by 2
Related Papers
The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma
|The American Journal of Surgical Pathology|2020|705
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
|JAMA|2015|420
Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
|Clinical Cancer Research|2013|358